Durvalumab: Phase I started

Gradalis Inc. (Dallas, Texas) said Mary Crowley Cancer Research began an open-label, U.S. Phase I trial of intradermal Vigil engineered autologous tumor cells in combination with 1,500 mg IV durvalumab every 4 weeks in about 33 patients. The first part will determine the dose of Vigil to be used for the second part, which will test the selected dose in combination with durvalumab in patients with no PD-L1 expression. ...